

Masaki Kato

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/826672/publications.pdf>

Version: 2024-02-01

72
papers

2,711
citations

257450

24
h-index

189892

50
g-index

75
all docs

75
docs citations

75
times ranked

3468
citing authors

#	ARTICLE	IF	CITATIONS
1	Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. <i>Molecular Psychiatry</i> , 2007, 12, 247-257.	7.9	487
2	Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. <i>Molecular Psychiatry</i> , 2010, 15, 473-500.	7.9	405
3	Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients. <i>Neuropsychobiology</i> , 2006, 53, 186-195.	1.9	143
4	ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 398-404.	4.8	126
5	The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. <i>Translational Psychiatry</i> , 2015, 5, e553-e553.	4.8	107
6	Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2009, 150B, 115-123.	1.7	89
7	Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 851-870.	2.8	83
8	Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. <i>International Clinical Psychopharmacology</i> , 2005, 20, 151-156.	1.7	74
9	Pharmacogenetic studies in depression: a proposal for methodologic guidelines. <i>Pharmacogenomics Journal</i> , 2008, 8, 90-100.	2.0	74
10	The relationship between circulating mitochondrial DNA and inflammatory cytokines in patients with major depression. <i>Journal of Affective Disorders</i> , 2018, 233, 15-20.	4.1	71
11	Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. <i>Molecular Psychiatry</i> , 2021, 26, 118-133.	7.9	71
12	Differences in quantitative EEG between frontotemporal dementia and Alzheimer's disease as revealed by LORETA. <i>Clinical Neurophysiology</i> , 2011, 122, 1718-1725.	1.5	69
13	Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population. <i>JAMA Neurology</i> , 2018, 75, 842.	9.0	52
14	Estimated cognitive decline in patients with schizophrenia: A multicenter study. <i>Psychiatry and Clinical Neurosciences</i> , 2017, 71, 294-300.	1.8	51
15	Augmentation Treatments with Second-generation Antipsychotics to Antidepressants in Treatment-resistant Depression. <i>CNS Drugs</i> , 2013, 27, 11-19.	5.9	45
16	Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder. <i>Frontiers in Psychiatry</i> , 2018, 9, 65.	2.6	38
17	The Alpha 2A-Adrenergic Receptor Gene Polymorphism Modifies Antidepressant Responses to Milnacipran. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 518-524.	1.4	30
18	Pharmacological management of depression: Japanese expert consensus. <i>Journal of Affective Disorders</i> , 2020, 266, 626-632.	4.1	30

#	ARTICLE	IF	CITATIONS
19	No Association of TPH1 218A/C Polymorphism with Treatment Response and Intolerance to SSRIs in Japanese Patients with Major Depression. <i>Neuropsychobiology</i> , 2007, 56, 167-171.	1.9	29
20	Antidepressant response and intolerance to SSRI is not influenced by G-protein $\beta 3$ subunit gene C825T polymorphism in Japanese major depressive patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1041-1044.	4.8	29
21	The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression. <i>Journal of Neural Transmission</i> , 2019, 126, 35-45.	2.8	27
22	HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pii125.	2.1	26
23	5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. <i>Psychiatry Research</i> , 2009, 167, 97-105.	3.3	25
24	The serotonin transporter gene and effectiveness of SSRIs. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 111-120.	2.8	24
25	Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects. <i>European Neuropsychopharmacology</i> , 2009, 19, 718-725.	0.7	24
26	Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: A subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study. <i>Psychiatry and Clinical Neuroscience</i> , 2015, 69, 34-42.	1.8	24
27	Remifentanyl in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 703-717.	3.2	24
28	Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression. <i>Psychiatry Research</i> , 2012, 198, 424-429.	3.3	23
29	HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 220-227.	1.4	22
30	The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial. <i>Neuropsychobiology</i> , 2016, 73, 35-42.	1.9	21
31	&p>Factors Associated with Non-Remission</p> in Bipolar Disorder: The Multicenter Treatment Survey for Bipolar Disorder in Psychiatric Outpatient Clinics (MUSUBI)</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 881-890.	2.2	21
32	Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs. <i>Translational Psychiatry</i> , 2015, 5, e513-e513.	4.8	20
33	Therapeutic Response to Paroxetine in Major Depressive Disorder Predicted by DNA Methylation. <i>Neuropsychobiology</i> , 2017, 75, 81-88.	1.9	19
34	Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT. <i>Journal of Psychiatric Research</i> , 2017, 89, 97-104.	3.1	17
35	Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. <i>BMC Psychiatry</i> , 2016, 16, 172.	2.6	16
36	Real-world clinical features of antidepressant prescribing patterns for outpatients with bipolar disorder. <i>BMC Psychiatry</i> , 2020, 20, 555.	2.6	16

#	ARTICLE	IF	CITATIONS
37	Pharmacological management of bipolar disorder: Japanese expert consensus. <i>Bipolar Disorders</i> , 2020, 22, 822-830.	1.9	16
38	Factors Associated with Doses of Mood Stabilizers in Real-world Outpatients with Bipolar Disorder. <i>Clinical Psychopharmacology and Neuroscience</i> , 2020, 18, 599-606.	2.0	16
39	Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. <i>Psychiatry and Clinical Neurosciences</i> , 2009, 63, 322-328.	1.8	15
40	Clinical features related to rapid cycling and one-year euthymia in bipolar disorder patients: A multicenter treatment survey for bipolar disorder in psychiatric clinics (MUSUBI). <i>Journal of Psychiatric Research</i> , 2020, 131, 228-234.	3.1	15
41	A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 40, 110-114.	4.8	13
42	Management of Chronic Depressive Patients with Residual Symptoms. <i>CNS Drugs</i> , 2013, 27, 53-57.	5.9	12
43	5-HTTLPR rs25531A > G Differentially Influence Paroxetine and Fluvoxamine Antidepressant Efficacy. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 131-132.	1.4	12
44	Polymorphism of rs3813034 in Serotonin Transporter Gene SLC6A4 Is Associated With the Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Response in Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 27-31.	1.4	11
45	Estimated model of psychotropic polypharmacy for bipolar disorder: Analysis using patients' and practitioners' parameters in the MUSUBI study. <i>Human Psychopharmacology</i> , 2021, 36, e2764.	1.5	11
46	Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design. <i>Neuropsychopharmacology Reports</i> , 2019, 39, 241-246.	2.3	10
47	Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus. <i>Pharmacopsychiatry</i> , 2021, 54, 60-67.	3.3	10
48	Syndrome of inappropriate secretion of anti-diuretic hormone in an elderly depressive patient receiving paroxetine: a case report. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 433-434.	2.7	9
49	Differences in prescription patterns between real-world outpatients with bipolar I and II disorders in the MUSUBI survey. <i>Asian Journal of Psychiatry</i> , 2022, 67, 102935.	2.0	9
50	Delirium Associated with Paroxetine in an Elderly Depressive Patient: A Case Report. <i>Pharmacopsychiatry</i> , 2007, 40, 199-200.	3.3	8
51	Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients. <i>Neuropsychobiology</i> , 2015, 72, 118-125.	1.9	8
52	Multiple Pre-Treatment miRNAs Levels in Untreated Major Depressive Disorder Patients Predict Early Response to Antidepressants and Interact with Key Pathways. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3873.	4.1	8
53	Neuropsychological Evaluation and Cerebral Blood Flow Effects of Apolipoprotein E4 in Alzheimer's Disease Patients after One Year of Treatment: An Exploratory Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2015, 5, 414-423.	1.3	7
54	Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysis. <i>Journal of Psychiatric Research</i> , 2020, 129, 160-167.	3.1	7

#	ARTICLE	IF	CITATIONS
55	Changes in energy during treatment of depression: an analysis of duloxetine in double-blind placebo-controlled trials. <i>International Journal of Clinical Practice</i> , 2015, 69, 1139-1148.	1.7	6
56	Relationship Between Mood Episode and Employment Status of Outpatients with Bipolar Disorder: Retrospective Cohort Study from the Multicenter Treatment Survey for Bipolar Disorder in Psychiatric Clinics (MUSUBI) Project. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 2867-2876.	2.2	6
57	Pre-treatment plasma cytokine levels as potential predictors of short-term remission of depression. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 785-793.	2.6	6
58	Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission. <i>Neuropsychopharmacology Reports</i> , 2022, 42, 306-314.	2.3	6
59	Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 579-588.	3.2	5
60	Relationship Between Employment Status and Unstable Periods in Outpatients with Bipolar Disorder: A Multicenter Treatment Survey for Bipolar Disorder in Psychiatric Outpatient Clinics (MUSUBI) Study. <i>Neuropsychiatric Disease and Treatment</i> , 2022, Volume 18, 801-809.	2.2	5
61	Real-world clinical predictors of manic/hypomanic episodes among outpatients with bipolar disorder. <i>PLoS ONE</i> , 2021, 16, e0262129.	2.5	5
62	Determinants of three-year clinical outcomes in real-world outpatients with bipolar disorder: The multicenter treatment survey for bipolar disorder in psychiatric outpatient clinics (MUSUBI). <i>Journal of Psychiatric Research</i> , 2022, 151, 683-692.	3.1	5
63	Brain Volume-Related Polymorphisms of the Glycogen Synthase Kinase-3 β Gene and Their Effect on Antidepressant Treatment in Major Depressive Disorder. <i>Neuropsychobiology</i> , 2019, 78, 136-144.	1.9	4
64	Personality as a basis for antidepressant selection for patients with depression: A two-point outcome study at 4 and 8 weeks. <i>Journal of Affective Disorders</i> , 2022, 314, 27-33.	4.1	4
65	Olfactory reference syndrome treated by blonanserin augmentation. <i>Psychiatry and Clinical Neurosciences</i> , 2011, 65, 203-204.	1.8	3
66	Safety and effectiveness of controlled-release paroxetine in routine clinical practice: results of a postmarketing surveillance study of patients with depression. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 435.	2.2	2
67	Divergence of dose-response with asenapine: a cluster analysis of randomized, double-blind, and placebo control study. <i>CNS Spectrums</i> , 2022, 27, 369-377.	1.2	2
68	5-HTTLPR rs25531A > G Differentially Influence Paroxetine and Fluvoxamine Antidepressant Efficacy. <i>Journal of Clinical Psychopharmacology</i> , 2012, , 1.	1.4	1
69	1/4 1/4 ZæŠ—ã†ãè—ã@ãá;œã°æ¬ã>ãã•ã—ã†ã@è—ç†éã¼ã¼çš,,ã,cãf—ãfãf¼ããfã@ã°èf½æ€S. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2013, 44, 117-122.	0.1	0
70	Prediction of Treatment Response in Depression Based on Genetic Factors from the Practical Viewpoint. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2013, 44, 117-122.	0.1	0
71	Sevoflurane anesthesia in electroconvulsive therapy: a meta-analysis of randomized controlled trials. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO3-1-90.	0.0	0
72	PGx in Depression, Current Status and Future Prospects for Clinical Use. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, JSCPT-FS-3.	0.0	0